



BACKGROUND INFORMATION

The isoflavonoids in soy foods are reported to have numerous medicinal properties. Many studies have shown that these isoflavonoids, which are plant estrogens (phytoestrogens), play an important role in the prevention of cancer¹, cardiovascular disease² and osteoporosis.^{3a-d} Most important and abundant among these plant estrogens that are found in soy, are genistein and daidzein (Fig. 1).

Figure 1: Chemical structures of genistein and daidzein




There are a number of hypotheses explaining the health benefits and the biochemical action of genistein and daidzein. Barnes et. al.⁴ viewed genistein as a phytoestrogen that exhibits chemopreventive properties by acting as an estrogen antagonist. The anti-cancer drug, tamoxifen, has a similar pharmacological effect. This basic hypothesis was further expanded by Akiyama et. al.,⁵ who showed that genistein is an excellent and specific inhibitor


of protein tyrosine kinases. Many cellular biochemical pathways, initiated by extracellular growth factors, proceed by the phosphorylation of tyrosine using protein tyrosine kinases. These pathways are especially important in transformed cells since more than half of the protein products of cellular oncogenes undergo uncontrolled tyrosine phosphorylation⁶. In light of these investigations, genistein has been a subject of numerous studies involving protein tyrosine kinase inhibition. Genistein inhibits the proliferative growth of many cancer cells in tissue culture^{7a,b} and inhibits the appearance of tumors in animal models of breast cancer⁸ and skin cancer,^{9a,b} and is active against colonic cancer.^{10a,b} Apart from the anti-cancer applications, genistein is also a good inhibitor of α -glucosidase (invertase).¹¹ Genistein is a reversible, slow binding, non-competitive inhibitor of α -glucosidase with a K_i value of 5.7×10^{-8} M. These results indicate that genistein can be used to treat certain metabolic disorders. Isoflavones are also known to lower the incidence of coronary heart disease and mitigate the effects of hot flashes in postmenopausal women. In many cases treatment of hot flashes by isoflavones has proven safer and more effective than estrogen replacement therapy.

Isoflavones are absorbed in the gut just like any other xenobiotic. The absorption of a xenobiotic through the gastrointestinal tract depends on several factors. The xenobiotic should be hydrophilic enough to dissolve in the aqueous environment but at the same time should be sufficiently hydrophobic to be soluble in the gut membrane. The charge on the xenobiotic also plays a major role in its absorption. This charge is determined by the pH of the medium, which in this case is the small or large intestine, whose pH is close to 7.8. In most non-fermented soy foods, isoflavones exist as conjugates with glucose, as their malonyl or acetyl esters (Fig. 2). In many cases though, the esters are hydrolyzed when soy foods undergo heat treatment. This leaves genistin as the major isoflavone component. Genistein is a very hydrophilic molecule and thus is not absorbed well by the body through the gut. Genistein, on the other hand, has the right balance of hydrophilicity and hydrophobicity to efficiently get absorbed by the body. Experiments on human subjects have shown that the aglycone form, genistein, is absorbed faster and in greater amounts than its glycosylated conjugate, genistin.¹²


Figure 2



6''-O-Malonylgenistein



6''-O-Acetylgenistein



Genistin

Enzymes capable of cleaving the β -ether linkage of the glycosylated isoflavones could have applications in soy food and beverage products. Scheme 1 describes the reaction catalyzed by these enzymes.


The human body does not produce the enzyme that is capable of hydrolyzing the glycosidic linkage between the glucose molecule and the isoflavone. Some bacterial flora present in human gut do produce this enzyme but not all humans carry these bacteria. Consequently many people who ingest soy food are not receiving the benefits of isoflavones. National Enzyme Company has developed a unique blend of enzymes, **Isolase**[®], that is capable of hydrolyzing this β -glycosidic linkage and thus release free isoflavones, which are more bioavailable.

To test the efficacy of **Isolase**[®], National Enzyme Company conducted a clinical trial in collaboration with Iowa State University. The trial was a double blind study where subjects were administered soy protein drink with and without **Isolase**[®]. Plasma samples were analyzed after 0, 3 and 24 hours. Analysis of plasma samples taken at 3 hours showed that **Isolase**[®] doubles the absorption of isoflavones.

Isolase[®] is stable in gastric juice, has a wide pH range and thus works throughout the GI tract. **Isolase**[®] is also heat stable up to 85 °C for 5 minutes.

Isolase[®] can be incorporated into many soy foods and will increase the bioavailability of isoflavones.

Scheme 1



References:

1. Messina, M.; Persky, V.; Setchell, K.D.R.; Barnes, S. "Soy intake and cancer risk: A review of in vitro and in vivo data." *Nutr. Cancer*, 21: 113-131, (1994)
2. Anderson, J.W.; Johnstone, B.M.; Cook-Newell, M.E. "Meta-analysis of the effects of soy protein intake on serum lipids." *New Engl. J. Med.*, 333: 276-282, (1995)
3. a) Kalu, D.N.; Masoro, E.N.; Yu, B.P.; Hardin, R.R.; Hollis, B.W. "Modulation of age-related hyperparathyroidism and senile bone loss in Fischer rats by soy protein and food restriction." *Endocrinol.*, 122: 1847-1854, (1988).
b) Blair, H.C.; Jordan, S.E.; Peterson, T.G.; Barnes, S. "Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats." *J. Cell. Biochem.*, 61: issue 4, 629-637, (1996)
c) Kao, P.C.; P'eng, F.K. "How to reduce the risk factors of osteoporosis in Asia?" *Chinese Med. J.*, 55: 209-213, (1995).
d) Messina, M. "Modern application for an ancient bean: soybeans and the prevention and treatment of chronic disease." *J. Nutr.*, 125: 567S-569S, (1995).
4. Barnes, S.; Grubbs, C.; Setchell, K.D.R.; Carlson, J. "Soybeans inhibit mammary tumors in models of breast cancer" in *Mutagens and carcinogens in the diet*, ed. Pariza, M.; Liss, A.R.; New York, pp. 239-253, (1990).
5. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.; Itoh, N.M.; Shibuya, M.; Fukagami, Y. "Genistein, a specific inhibitor of tyrosine-specific protein kinase" *J. Biol. Chem.*, 262: 5592-5595, (1987).
6. Cantley, L.C.; Auger, C.; Carpenter, B.; Duckworth, R.; Kapeller, R.; Soltoff, S. "Oncogenes and signal transduction" *Cell*, 64: 281-302, (1991).
7. a) Peterson, T.G.; Barnes, S. "Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene" *Biochem. Biophys. Res. Commun.*, 179: 661-667, (1991).
b) Peterson, T.G.; Barnes, S. "Genistein potently inhibits the growth of human primary breast epithelial cells: correlation with lack of genistein metabolism" *Mol. Biol. Cell*, 5: 384a, (1994).
8. Lamartiniere, C.A.; Moore, J.A.; Holland, M.; Barnes, S. "Genistein and chemoprevention of breast cancer" *Proc. Soc. Exptl. Biol. Med.*, 208: 120-123, (1995).
9. a) Wei, H.; Wei, L.; Frankel, K.; Bowen, R.; Barnes, S. "Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein" *Nutr. Cancer*, 20: 1-12, (1993).
b) Wei, H.; Bowen, R.; Cai, Q.; Barnes, S.; Wang, Y. "Antioxidant and antipromotional effects of the soybean isoflavone genistein" *Proc. Soc. Exptl. Biol. Med.*, 208: 124-130, (1995).
10. a) Pereira, M.A.; Barnes, L.H.; Rassman, V.L.; Kelloff, G.V.; Steele, V.E. "Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventative agents" *Carcinogenesis*, 15: 1049-1054, (1994).
b) Helms, J.R.; Gallaher, J.J. "The effect of dietary soy protein isolate and genistein on the development of preneoplastic lesions (aberrant crypts) in rats" *J. Nutr.*, 125: 802S, (1995).
11. Lee, D.H.; Lee, S.H. "Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor" *FEBS Lett.*, 501(1): 84-86, (2001).
12. Barnes, S.; Sfakianos, J.; Coward, L.; Kirk, M. "Soy isoflavonoids and cancer prevention" *Dietary Phytochemicals and Cancer Prevention and Treatment*, chap.7, 87-100.